Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2016

View Archived Issues

Mitochon raises funding to advance MP-101 into clinic

MacroGenics and Janssen enter collaboration and license agreement to develop MGD-015

AXIM Biotechnologies launches trials for AX-1602

Chugai's novel T cell-redirecting antibody targets both CD3 and glypican-3

Synthon begins second part of SYD-985 clinical trial

Levels of BAFF and APRIL may be useful as biomarkers of APAP

Cell and Gene Therapy Catapult and University of Aberdeen create new company, Islexa

FDA grants priority review to sBLA for Genmab 's ofatumumab

Enrollment open in phase I study of Lymfactin for breast cancer-associated secondary lymphedema

Celator's Vyxeos gains FDA breakthrough status for AML

Repros reports promising data from phase IIb study of oral Proellex

Enanta Pharmaceuticals patents antihepatitis agents

Lysosomal Therapeutics discloses beta-glucocerebrosidase activators

Bicycle Therapeutics describes anticancer agents

NIH-funded phase IIb/III trial to evaluate HIV vaccine regimen in South Africa

Zealand Pharma reports development of GIPR receptor agonists

JNJ-61178104 begins phase I study under Genmab and Janssen's DuoBody collaboration

Sanofi presents mitochondrial complex I inhibitors

Pelican Therapeutics wins NCPD award for the development of TNFRSF25 agonists

Results from phase I study of RG-7716 for wet AMD

Abpro signs agreements with Massachusetts General Hospital and Brigham and Women's Hospital

VASH2 shows promise as a therapeutic target for CRPC

Novartis establishes global clinical program for heart failure Fortihfy

Biocept launches liquid biopsy test to detect RET oncogene fusions

Neurotrope enters collaboration with IRSF to study bryostatin in Rett syndrome

Beta launch of spinal deformity molecular diagnostic test

Eureka Therapeutics CAR-T therapy targeting antigen/MHC complexes to enter phase I

NLRP3-inflammasome responses show potential as therapeutic targets for SSI asthma

Merrimack begins biomarker-based phase I trial of MM-151 in cancer